Nirmal Bang upgrades Natco Pharma to a buy; here's why
Updated: 01 Jun 2022, 10:49 AM IST
- The brokerage firm highlighted that Natco Pharma’s Q4FY22 revenue at ₹596.9 crore was significantly higher than its expectation of ₹450.4 crore.
In the next two-three years, Natco should be able to generate significant cash flow from the Revlimid opportunity. Photo: Pixabay